RESEARCH TRIANGLE PARK, N.C. -- (BUSINESS WIRE) -- For the second year in a row, Quintiles has been named the CRO industry leader in Phase I services according to respondents in Industry Standard Research’s (ISR) report, CRO Quality Benchmarking Phase I Service Providers (2014). In this year’s survey, Quintiles was recognized as the “overwhelming leader” when survey respondents were asked to identify CROs they consider leaders in the Phase I space. This announcement follows Quintiles’ recognition, also for the second year in a row, as the industry leader that best differentiates itself on service quality for Phase II/III research in an earlier ISR report released in April.
In this new report, Quintiles was mentioned by 60% of the 113 decision-makers who were surveyed around the globe as the industry-leading service provider. In addition to leading all large CROs in service provider loyalty – a compilation of overall satisfaction, willingness to recommend and likelihood to use again – Quintiles also was identified as the service provider that respondents from small and mid-sized pharmaceutical companies prefer to work with out of all CROs.
“I am delighted to see that Quintiles once again is the leader by a wide margin among Phase I service providers,” said Oren Cohen, M.D., senior vice president, Early Clinical Development at Quintiles. “I believe that the expertise, experience and dedication of our staff, as well as our ability to offer integrated solutions - including clinical execution, project management, data management, biostatistics, medical writing, bioanalysis, pharmacokinetic analysis, digital ECG, genomics and more – are resonating with the ‘2014 and beyond’ needs of the biopharmaceutical industry. These are all tools that customers can leverage to get to the proof of concept stage with a higher degree of certainty, which helps improve their probability of success.”
Survey respondents also identified Quintiles as the “best service provider for differentiation” based on service quality, with particular strengths in: therapeutic expertise, scientific knowledge, data quality, financial strength/stability, and local market/regulatory knowledge. In terms of customers’ willingness to recommend to friends or colleagues, and likelihood to use again, Quintiles was again the leader among large CROs.
Quintiles (NYSE: Q) is the world’s largest provider of biopharmaceutical development and commercial outsourcing services with a network of more than 29,000 employees conducting business in approximately 100 countries. We have helped develop or commercialize helped develop or commercialize all of 2013’s top-100 best-selling drugs on the market. Quintiles applies the breadth and depth of our service offerings along with extensive therapeutic, scientific and analytics expertise to help our customers navigate an increasingly complex healthcare environment as they seek to improve efficiency and effectiveness in the delivery of better healthcare outcomes. To learn more about Quintiles, please visit www.quintiles.com.
Click here to subscribe to Mobile Alerts for Quintiles.